» Articles » PMID: 1869840

Effect of Prior Infection with Virulent Shigella Flexneri 2a on the Resistance of Monkeys to Subsequent Infection with Shigella Sonnei

Overview
Journal J Infect Dis
Date 1991 Sep 1
PMID 1869840
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

All virulent shigellae have large plasmids. Plasmid-associated genes encode the expression of membrane-associated proteins (MAP), some of which correlate with the ability to invade susceptible epithelial cells. These MAP are serologically related in all of the shigella serotypes and evoke an antibody response after infection. To determine whether the MAP have a significant role in protection, 24 monkeys were infected with virulent Shigella flexneri 2a. After recovery, one group (with controls) was rechallenged with S. flexneri 2a; another group (with controls) was fed Shigella sonnei. The animals that were rechallenged with S. flexneri 2a were protected, while those that were fed S. sonnei experienced the same incidence of disease as controls. No differences in serum immune response to MAP after primary infection with S. flexneri were detected in immunoblots using lysates of S. flexneri or S. sonnei or in ELISA using water extracts of these strains.

Citing Articles

A broad spectrum Shigella vaccine based on VirG multiepitope region produced in a cell-free system.

Desalegn G, Abrahamson C, Ross Turbyfill K, Pill-Pepe L, Bautista L, Tamilselvi C NPJ Vaccines. 2025; 10(1):6.

PMID: 39805874 PMC: 11731012. DOI: 10.1038/s41541-025-01064-6.


Shigella sonnei: epidemiology, evolution, pathogenesis, resistance and host interactions.

Scott T, Baker K, Trotter C, Jenkins C, Mostowy S, Hawkey J Nat Rev Microbiol. 2024; .

PMID: 39604656 DOI: 10.1038/s41579-024-01126-x.


Evaluation of a Quadrivalent Serotype 2a, 3a, 6, and O-Specific Polysaccharide and IpaB MAPS Vaccine.

Boerth E, Gong J, Roffler B, Hancock Z, Berger L, Song B Vaccines (Basel). 2024; 12(10).

PMID: 39460258 PMC: 11510904. DOI: 10.3390/vaccines12101091.


A next-generation GMMA-based vaccine candidate to fight shigellosis.

Rossi O, Citiulo F, Giannelli C, Cappelletti E, Gasperini G, Mancini F NPJ Vaccines. 2023; 8(1):130.

PMID: 37670042 PMC: 10480147. DOI: 10.1038/s41541-023-00725-8.


Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry.

Kelly M, Mandlik A, Charles R, Verma S, Calderwood S, Leung D Vaccine. 2023; 41(34):4967-4977.

PMID: 37400283 PMC: 10529421. DOI: 10.1016/j.vaccine.2023.06.052.